Medicare AdvantageCoverageMedium impact
MA07.030c, Photodynamic Therapy (PDT) Using Porfimer Sodium (Photofrin®)
Independence Blue Cross·Oncology, Dermatology, Gastroenterology +1 more·Pharmacy
Effective date
Jul 9, 2025
We identified it
Jun 19, 2026
Summary
Medicare Advantage policy MA07.030c for Photodynamic Therapy (PDT) using Porfimer Sodium (Photofrin®) has been reissued and becomes effective July 9, 2025. This is a fresh pharmacy-related policy update that may impact coverage or billing requirements for this specialized cancer treatment.
Action Required
By July 9, 2025: Billing team should review the full policy details at the provided URL to understand any changes to coverage, prior authorization, or billing requirements for Photodynamic Therapy using Porfimer Sodium. Update billing protocols and inform providers who perform PDT procedures of any new requirements.